Probing marine brown macroalgal phlorotannins as antiviral candidate against SARS-CoV-2: molecular docking and dynamics simulation approachArticle Published on 2022-12-012022-11-15 Journal: Molecular diversity [Category] COVID19(2023년), SARS, 치료제, [키워드] 3CLpro antagonist Antiviral antiviral intervention approach AutoDock binding affinities binding affinity candidate Compound compounds COVID-19 COVID-19 therapeutics Cys145 deviation docking Drug discovery drug-likeness Efficacy evaluated GLN189 Glu166 immunostimulatory inhibit interaction site MD simulation molecular molecular docking Molecular docking and dynamics simulation over Phlorotannin polyphenol Probing RdRP reported SARS-CoV-2 SARS-CoV-2 replication SARS-CoV-2. selected target protein target proteins targets therapeutic Thr190 were assessed [DOI] 10.1007/s11030-022-10383-y PMC 바로가기
Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronavirusesArticle Published on 2022-11-052022-11-15 Journal: Scientific Reports [Category] SARS, 신약개발, 치료제, [키워드] Analysis common cold Coronaviruses Compound COVID-19 COVID-19 therapeutics cytotoxicity effective gene expression profile globe Heat shock homoharringtonine host cell response host response in silico in vitro modulating other coronavirus pandemic pathway Prevent provided reported SARS-CoV-2 SARS-CoV-2 biology screened severe symptoms tanespimycin target tested unique Vaccine viral infection [DOI] 10.1038/s41598-022-21984-w PMC 바로가기
Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crisesArticle Published on 2022-11-012022-11-16 Journal: Biophysical chemistry [Category] 신약개발, [키워드] affected analysis approach Cheminformatics clinical clinical study clinical trials complex compounds COVID-19 COVID-19 pandemic COVID-19 therapeutics deep learning develop Disease progression drug Drug repurposing drugs effort global healthcare Health help identify in silico Infectious disease information Intervention lack limitation machine machine learning miRNA MONITOR New pandemic pharmacological strategy Regulatory Research robust Side-effects System Systems biology systems biology. targets therapeutic therapeutic target Treatment strategies [DOI] 10.1016/j.bpc.2022.106891 PMC 바로가기
COVID-19: Vaccines and therapeuticsArticle Published on 2022-11-012022-11-16 Journal: Bioorganic & medicinal chemistry letters [Category] SARS, 변종, [키워드] acute respiratory syndrome approved communicable coronavirus Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 therapeutics COVID-19 vaccines death deaths disease effective Health highlight Infection Measures New New variants of SARS-CoV-2 Protective reported Research SARS-CoV-2 SARS-CoV-2. Therapeutic strategies Treatment triggered Vaccine variant virus [DOI] 10.1016/j.bmcl.2022.128987 PMC 바로가기
Notes From the Field: Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability – United States, December 23, 2021-August 28, 2022Article Published on 2022-10-282022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] 치료제, [키워드] Analysis Antiviral collected COVID-19 COVID-19 therapeutics Critical death Department Dispensing distribution drug Emergency use authorization EUA FDA food higher risk highlight Hospitalization Human indicated Intervention medication medium Mild Moderate COVID-19 molnupiravir oral Patient Paxlovid provide recipient reduce risk service United States vulnerability [DOI] 10.15585/mmwr.mm7143a3 PMC 바로가기
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesArticle Published on 2022-10-152022-11-16 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted age analyses analysis Analysis aRR association B.1.1.529 benefit BNT162b2 booster booster dose Booster vaccine calculated ChAdOx1 nCoV-19 Chronic kidney disease Committee Comorbidities Comorbidity conducted core covariates COVID-19 COVID-19 hospitalisation COVID-19 infection COVID-19 therapeutics COVID-19 vaccination current death dominant Edinburgh England event group Health health condition high risk hospitalisation identify immunisation Immunosuppressant increased risk individual initial Innovation Ireland male Medical Research Council meta-analyses Moderna mortality data mRNA-1273 Multimorbidity National of BNT162b2 offer older adult outcome outcomes Oxford-AstraZeneca per 1000 person-year per 1000 person-years Pfizer-BioNTech Poisson regression model primary care prospective cohort prospective cohort study rate ratio receiving reduced reduced risk remained risk risk factor RT-PCR testing SARS-COV-2 infection Scottish severe COVID-19 Sex those with comorbidity university vaccination Vaccine vaccine dose vaccine group variant [DOI] 10.1016/S0140-6736(22)01656-7 PMC 바로가기
Calibration and Validation of a Mechanistic COVID-19 Model for Translational Quantitative Systems Pharmacology – A Proof-of-Concept Model Development for RemdesivirArticle Published on 2022-10-012022-11-15 Journal: Clinical Pharmacology and Therapeutics [Category] COVID19(2023년), SARS, 치료제, [키워드] accelerate Administered antibody approach calibrated calibration clinical Clinical data Clinical outcome clinical setting clinical study Clinical trial design coronavirus disease Course COVID-19 COVID-19 disease COVID-19 therapeutics Cytokines development disease drug candidate example global pandemic immune responses immunological in silico include intravenously lymphopenia metabolism metabolite Mild Model Patient pharmacological Pharmacology Placebo predict provide quantitative framework Remdesivir responses severe COVID-19 System the disease the primary endpoint Therapies therapy Time to recovery translate validation viral titer virus infection [DOI] 10.1002/cpt.2686 PMC 바로가기
A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemicsArticle Published on 2022-10-012022-11-15 Journal: Clinical and translational science [Category] COVID19(2023년), SARS, 치료제, [키워드] Anti-inflammatory Antiviral approved authorization chloroquine/hydroxychloroquine Clinical data Clinical efficacy clinical evidence clinical study clinical trial coronavirus disease COVID-19 COVID-19 pandemic COVID-19 therapeutics Critical demonstrated drug Efficacy Emergency Emergency use authorization EUA Evidence FDA food Guidance majority medication Pandemics public health emergency question Randomized controlled trial RCT Regulatory Resilience statistically significant submitted subsequent Support supported therapeutic withdrawn [DOI] 10.1111/cts.13384 PMC 바로가기
Antiviral COVID-19 protein and molecular docking: In silico characterization of various antiviral compounds extracted from Arisaema jacquemontii BlumeArticle Published on 2022-09-232022-11-15 Journal: Frontiers in Public Health [Category] 치료제, [키워드] 6LU7 A. jacquemontii Blume affinity Analysis Anti-COVID protein antimalarial antioxidant Antiviral antiviral activities Antiviral compound Araceae Arisaema binding binding affinity binding energy Cobra Cobra lily Compound compounds COVID-19 COVID-19 therapeutics Diseases docked docking effective evaluated FIVE Gas Chromatography-Mass Spectrometry GC-MS highest in silico Interaction interactions molecular phytochemical. protease Protein SARS virus selected shown these compound treat viral infections [DOI] 10.3389/fpubh.2022.964741 PMC 바로가기
Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemicArticle Published on 2022-09-012022-10-05 Journal: American journal of obstetrics & gynecology MFM [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] administration Admission adverse events anaphylaxis Atlanta authorization benefit casirivimab and imdevimab Clinical course Clinical outcome Cohort cohort of patient COVID-19 COVID-19 illness COVID-19 pandemic COVID-19 therapeutics death drug Effect Efficacy eligible Emergency food groups high-risk population higher risk Hospital stay Hospitalization Hypothesis increased risk individual Infection instance intensive care less Maternal morbidity Memorial monoclonal antibodies monoclonal antibody morbidity and mortality need for oxygen Neonatal Neonatal morbidity no significant difference nonpregnant novel therapies offered outcome outcomes Oxygen requirement patients with SARS-CoV-2 pharmacologic treatment Placebo polymerase chain positive Pregnancy pregnant pregnant patient pregnant patients pregnant population receive reduce reduced REGEN-COV released resolved Respiratory illness retrospective cohort study risk Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 viral load severe COVID-19 severe disease Shortness of breath shown side statistically significant difference Symptom tested therapy thought treated Treatment treatment guideline Trial trials ventilatory support were excluded worsening [DOI] 10.1016/j.ajogmf.2022.100673 [Article Type] Article